Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8364MR)

This product GTTS-WQ8364MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8364MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9932MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ5998MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ6030MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ13827MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ13577MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ7027MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ13148MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ13419MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW